Today, GoPath has announced that two abstracts accepted at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place virtually from June 4 – 8.

• Digital PCR-based Plasma Cell-free DNA K-Ras Mutations Analysis and Clinical Implication in Pancreatic Cancer
• Overview: This study examined liquid biopsy assay and in particular, an analysis of cell-free DNA (cfDNA), which has emerged as a promising noninvasive diagnostic approach in oncology, with the respect to the identification of minimal residual diseases, monitoring treatment response, detection recurrence and metastasis, and identification of chemo-resistance mechanisms. Digital PCR-based plasma cfDNA assay for K-Ras mutation is a promising tool for the diagnosis of PDAC and is comparable to tissue-based assays. Larger prospective studies can substantiate this and explore their roles in the prediction and early detection of recurrence of PDAC.
• This abstract has been accepted for publication in JCO (Abstract number e16215, DOI: 10.1200/JCO.2021.39.15_suppl.e16215)
• Differential gene expression of tight-junction proteins and their correlation with PRSS8 and prognosis in colorectal cancer
• Overview: TJPs play a major role in maintaining the integrity of the intestinal epithelia and regulate several key signaling pathways in cancers. Dysregulation of tight junction and adheren junction has been shown to be associated with disruption of mucosa barriers, chronic colitis, early onset of colorectal carcinogenesis, epithelial mesenchymal transition and cancer metastasis. Our recent studies have shown that intestinal conditional knockout of the Press8 (protease serine 8) gene causes disruption of intestinal epithelial homeostasis, spontaneous inflammation and tumorigenesis in mouse intestine. Both in vitro study and meta-analysis showed differential gene expression of tight junction proteins in colorectal cancer. Thus, TJPs could be used as biomarkers for the monitoring of early onset colorectal carcinogenesis, progression and for the prediction of prognosis.
• This abstract has been accepted for in JCO (Abstract number e15548, DOI: 10.1200/JCO.2021.39.15_suppl.e15548)

About GoPath Laboratories
GoPath Laboratories is a full-service cancer genetics, molecular and anatomic pathology diagnostic reference laboratory. We provide cutting-edge testing technologies, laboratory and pharmaceutical partnerships, and global/technology-only options.
We offer comprehensive, innovative solutions to questions regarding a patient’s health: GeneticsNow® (cancer genetic testing), OncoTarget® (targeted therapy diagnostic testing), and OncoTracking™ (cancer recurrence testing). These solutions were developed by building the right team, utilizing the best diagnostic technology platforms, and partnering with key industry leaders, all with a shared goal of doing our part to beat cancer.